Cargando…

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

OBJECTIVE: Assess the effect of abatacept on progression of structural damage over 2 years in patients with rheumatoid arthritis who had an inadequate response to methotrexate. METHODS: 539 patients entered an open-label extension of the AIM (Abatacept in Inadequate responders to Methotrexate) trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Genant, H K, Peterfy, C G, Westhovens, R, Becker, J-C, Aranda, R, Vratsanos, G, Teng, J, Kremer, J M
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2008
Materias:	Extended Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2569144/ https://www.ncbi.nlm.nih.gov/pubmed/18086727 http://dx.doi.org/10.1136/ard.2007.085084

Ejemplares similares

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
por: Emery, P, et al.
Publicado: (2009)

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
por: Kremer, Joel M, et al.
Publicado: (2011)

Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment
por: Westhovens, R, et al.
Publicado: (2004)

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
por: Schiff, M, et al.
Publicado: (2008)

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
por: Westhovens, R, et al.
Publicado: (2009)

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis
por: Westhovens, Rene, et al.
Publicado: (2015)

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium
por: Wijbrandts, C A, et al.
Publicado: (2008)

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
por: Schiff, Michael, et al.
Publicado: (2011)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis
por: Peterfy, Charles, et al.
Publicado: (2016)

Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)
por: Smolen, Josef S., et al.
Publicado: (2015)

Local and systemic glucocorticoid metabolism in inflammatory arthritis
por: Hardy, R, et al.
Publicado: (2008)

Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis
por: Ho, P Y P C, et al.
Publicado: (2008)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial
por: Conaghan, Philip G, et al.
Publicado: (2013)

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
por: Lutt, Joseph R
Publicado: (2009)

Septic arthritis in Iceland 1990–2002: increasing incidence due to iatrogenic infections
por: Geirsson, Á J, et al.
Publicado: (2008)

Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial
por: van der Heijde, D, et al.
Publicado: (2008)

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
por: Simon, T A, et al.
Publicado: (2009)

Abatacept: the evidence for its place in the treatment of rheumatoid arthritis
por: Köller, Marcus D.
Publicado: (2007)

The Use of Abatacept for the Treatment of Felty Syndrome in Rheumatoid Arthritis
por: Chin, Rishika V, et al.
Publicado: (2023)

Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study
por: Buch, M H, et al.
Publicado: (2009)

Evidence for the Differential Distribution of at Least Two Adrenomedullin Receptor Subtypes in the Rat Brain
por: Chabot, J.-G., et al.
Publicado: (2001)

Pneumocystis jirovecii Pneumonia in a Patient with Rheumatoid Arthritis Treated with Abatacept
por: Ospina, Fabio E., et al.
Publicado: (2014)

Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study
por: Westhovens, R., et al.
Publicado: (2020)

Subcutaneous abatacept in rheumatoid arthritis: A real-life experience
por: Sarmiento-Monroy, Juan Camilo, et al.
Publicado: (2019)

Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
por: Yokoyama-Kokuryo, Waka, et al.
Publicado: (2020)

Efficacy and safety of abatacept in patients with rheumatoid arthritis with previous malignancy
por: Kunishita, Yosuke, et al.
Publicado: (2023)

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
por: Alten, Rieke, et al.
Publicado: (2016)

Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
por: Harrold, Leslie R., et al.
Publicado: (2023)

Modulation of the Expression of Calcitonin Gene-Related Peptide and Substance P in Cultured Dorsal Root Ganglia by Opioid Receptor Agonists. Involvement of the PKC Pathway
por: Bolanger, S., et al.
Publicado: (2001)

Multiple Receptor Subtypes for the CGRP Super-Family
por: Quirion, R., et al.
Publicado: (2001)

Peripheral Nerve Injury and CGRP Receptor Antagonist Modulate RCP-1 Expression in Primary Sensory Neurons and in Neurons of the Spinal Cord
por: Ma, W., et al.
Publicado: (2001)

Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis
por: Rakieh, Chadi, et al.
Publicado: (2014)

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Recommendations for the content and conduct of European League Against Rheumatism (EULAR) musculoskeletal ultrasound courses
por: Naredo, E, et al.
Publicado: (2008)

Cgrp Release and Synergistic Interactions with Nitric Oxide: Implications for Pathogenesis of Septic Shock and the Vascular Problems of Diabetes Mellitus and Aging
por: Fiscus, R.R., et al.
Publicado: (2001)

The Effect on CGRP-Binding of Mutations to the Hydrophilic Residues within the First Transmembrane Region of Human Calcitonin Receptor-Like Receptor (CRLR)
por: Conner, A. C., et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_g784armhmvousfnk7s6plh3en6